ACI "Maximizing Pharmaceutical Patent Life Cycles" Conference, New York, October 24-25

American Conference Institute will hold its eighth annual "Maximizing Pharmaceutical Patent Life Cycles" conference October 24-25 in New York.  According to ACI, this is the "one and only event that has consistently allowed brand name and generic drug makers to benchmark their companies' current strategies and tactics against competitors in both camps."

The agenda includes many topics covered on Orange Book Blog.  Specific talks include:

• "KSR and the New Standard for Obviousness: Exploring Its Impact on Primary and Secondary Pharmaceutical Patents"
• "Brand Name and Generic Pharmaceutical Patent Settlements: Pending Legislation, Key Cases and Strategies to Employ"
• "Patent and Non-Patent Exclusivity--New Developments Affecting the Basics and Beyond"
• "Orange Book Listings and Delistings: New Controversies, Concerns and Considerations" (I'll be speaking on this panel)
• "Update on FDA Activities Relative to Pharmaceutical Patent Life Cycles" (by Elizabeth Dickinson, Assoc. Chief Counsel for Drugs, FDA)

In addition, two optional post-conference workshops are offered on October 26: a brand name master class entitled "New Strategies for Obtaining Pharmaceutical Patent Extensions Post-KSR" and a generics master class entitled "Updated Drafting Guidelines for Paragraph IV Certifications and Notice Letters."

For more information or to register, please visit the conference website.

Orange Book Blog is a media partner of this conference.